Logo

Vivoryon and Simcere Sign a License Agreement for N3pE Amyloid-Targeting Medicines to Treat Alzheimer's Disease in Greater China

Share this

Vivoryon and Simcere Sign a License Agreement for N3pE Amyloid-Targeting Medicines to Treat Alzheimer's Disease in Greater China

Shots:

  • Vivoryon to receive an up front and is eligible to receive ~$565M upon achievement of development & commercial milestones along with royalties on sales
  • Simcere to get a regional license to develop and commercialize varoglutamstat (PQ912) and PBD-C06 in Greater China. The company acquired an option to advance PBD-C06 in the clinical program
  • The clinical development program in Greater China is planned to be complementary to Vivoryon's efforts in the EU and the US including the P-IIa VIVIAD trial in the EU & P-IIa/b study in the US which is expected to be initiated in H2’21

  | Ref: Vivoryon | Image: Vivoryon

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions